SCHEMBL9873139

SCHEMBL9873139

COC(c1ccccc1Cl)C(C)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.46
ADRB1 P08588 2/20 0.46
MGAM O43451 1/20 0.46
GAA P10253 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
AOC3 Q16853 1/20 0.42
CYP2D6 P10635 2/20 0.41
NFKB1 P19838 2/20 0.41
HIF1A Q16665 1/20 0.41
BLM P54132 1/20 0.40
CASP1 P29466 1/20 0.40
IDO1 P14902 2/20 0.38
TDO2 P48775 2/20 0.38
IDO2 Q6ZQW0 2/20 0.38
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 1/20 0.37
PNMT P11086 1/20 0.37
NISCH Q9Y2I1 1/20 0.37
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20604220 1.00 ADRB2 (0.46) ADRB2ADRB1MGAMGAASI
SCHEMBL16064821 0.85 ADRB2 (0.44) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL23347681 0.82 ADRB2 (0.40) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL10323550 0.81 ADRB2 (0.44) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL20604434 0.81 ADRB2 (0.44) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL10323549 0.81 ADRB2 (0.44) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL16064946 0.81 ADRB2 (0.47) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL20604519 0.81 ADRB2 (0.44) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL10323379 0.81 ADRB2 (0.44) ADRB2ADRB1AOC3CYP2D6NFKB1
SCHEMBL248196 0.81 ADRB2 (0.44) ADRB2ADRB1AOC3CYP2D6NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
EP-3423433-A1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES Bio-Pharm Solutions Co., Ltd. (KR) 2019-01-09 EP disclosed
US-5008461-A Converting glycol monoether using alumina, silica, phosphate, or zeolite catalyst BASF AKTIENGESELLSCHAFT (DE) 1991-04-16 US disclosed
EP-0390021-A2 Process for the preparation of benzylketones BASF Aktiengesellschaft (DE) 1990-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses STS, SULT2A1, SULT1A1 ADRB2 4255/4885ADRB1 4390/4885MGAM 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.